{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:33:25Z","timestamp":1793892805909,"version":"4.8.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":585,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>Bintrafusp alfa had a manageable safety profile and demonstrated preliminary clinical activity in heavily pretreated patients with solid tumors (including hepatocellular carcinoma) with no or limited treatment options. Findings from this study suggest bintrafusp alfa may be a novel therapeutic approach for patients with advanced solid tumors. Additional trials are needed to further explore safety and efficacy of bintrafusp alfa in specific tumor types.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of transforming growth factor-\u03b2 (TGF-\u03b2) RII receptor (a TGF-\u03b2 \u201ctrap\u201d) fused to a human immunoglobulin (Ig) G1 antibody blocking programmed death-ligand 1 (PD-L1). Bintrafusp alfa is designed to neutralize TGF-\u03b2 signaling by \u201ctrapping\u201d and sequestering all TGF-\u03b2 isoforms, and this trap function is physically linked to PD-L1 blockade in the tumor microenvironment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>NCT02699515 was a phase I, open-label, dose-escalation study of bintrafusp alfa (3, 10, and 20 mg\/kg every 2\u2009weeks) in Asian patients with advanced solid tumors, including a hepatocellular carcinoma (HCC) safety-assessment cohort. The primary objective was safety and tolerability; the secondary objective is best overall response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>As of August 24, 2018, 23 patients (including 9 in the HCC cohort) received bintrafusp alfa. Eight patients experienced treatment-related adverse events (TRAEs). Three patients had grade 3 TRAEs (13.0%; hypoacusis, hyponatremia, hypopituitarism, increased blood creatine phosphokinase, and intracranial tumor hemorrhage); one had grade 4 hyponatremia (4.3%). No treatment-related deaths occurred. In the dose-escalation cohort, two patients had a confirmed partial response, and 3 had stable disease (SD), for an overall response rate of 14.3% and a disease control rate (DCR) of 35.7%. In the HCC cohort, one patient had SD (DCR, 11.1%). A dose-proportional pharmacokinetics profile was observed at doses of &amp;gt;3 mg\/kg.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Bintrafusp alfa had a manageable safety profile and preliminary efficacy in heavily pretreated patients with advanced solid tumors, including HCC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2020-0249","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T17:28:22Z","timestamp":1587662902000},"page":"e1292-e1302","source":"Crossref","is-referenced-by-count":40,"title":["Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort"],"prefix":"10.1093","volume":"25","author":[{"given":"Toshihiko","family":"Doi","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Helwig","sequence":"additional","affiliation":[{"name":"Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morihiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Clinical Development Center, R&D Japan, North East Asia Hub, Merck Biopharma, Inc., Tokyo, Japan; an affiliate of Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Vugmeyster","sequence":"additional","affiliation":[{"name":"EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA; a business of Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"2021122510542204400_onco13305-bib-0001","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.immuni.2008.03.003","article-title":"Contextual regulation of inflammation: A duet by transforming growth factor-\u03b2 and interleukin-10","volume":"28","author":"Li","year":"2008","journal-title":"Immunity"},{"key":"2021122510542204400_onco13305-bib-0002","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","article-title":"Targeting the TGF\u03b2 signalling pathway in disease","volume":"11","author":"Akhurst","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"2021122510542204400_onco13305-bib-0003","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","article-title":"Mechanisms of TGF-\u03b2 signaling from cell membrane to the nucleus","volume":"113","author":"Shi","year":"2003","journal-title":"Cell"},{"key":"2021122510542204400_onco13305-bib-0004","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1365209","article-title":"PD-L1 inhibitors in the pipeline: Promise and progress","volume":"7","author":"Vanella","year":"2018","journal-title":"OncoImmunology"},{"key":"2021122510542204400_onco13305-bib-0005","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122510542204400_onco13305-bib-0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"2021122510542204400_onco13305-bib-0007","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2","volume":"10","author":"Lan","year":"2018","journal-title":"Sci Transl Med"},{"key":"2021122510542204400_onco13305-bib-0008","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2021122510542204400_onco13305-bib-0009","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1007\/s12325-019-01018-0","article-title":"Population pharmacokinetic analysis of bintrafusp alfa in different cancer types","volume":"36","author":"Wilkins","year":"2019","journal-title":"Adv Ther"},{"key":"2021122510542204400_onco13305-bib-0010","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1349589","article-title":"A novel bifunctional anti-PD-L1\/TGF-\u03b2 trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells","volume":"6","author":"David","year":"2017","journal-title":"Oncoimmunology"},{"issue":"suppl 15","key":"2021122510542204400_onco13305-bib-0011","article-title":"Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in patients with HPV associated cancers","volume":"36","author":"Strauss","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122510542204400_onco13305-bib-0012","article-title":"Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1","volume":"36","author":"Paz-Ares","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021122510542204400_onco13305-bib-0013","article-title":"Initial results from phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in patients with NSCLC refractory or resistant to prior anti\u2013PD-1\/anti\u2013PD-L1 agents","volume":"5","author":"Barlesi","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"suppl 4","key":"2021122510542204400_onco13305-bib-0014","doi-asserted-by":"crossref","first-page":"764a","DOI":"10.1200\/JCO.2018.36.4_suppl.764","article-title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in patients with heavily pretreated CRC: Preliminary results from a phase I trial","volume":"36","author":"Kopetz","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122510542204400_onco13305-bib-0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.21037\/qims.2018.03.08","article-title":"Clinical and imaging features of pituitary apoplexy and role of imaging in differentiation of clinical mimics","volume":"8","author":"Goyal","year":"2018","journal-title":"Quant Imaging Med Surg"},{"key":"2021122510542204400_onco13305-bib-0016","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3171\/jns.1981.55.2.0187","article-title":"Pituitary apoplexy: Its incidence and clinical significance","volume":"55","author":"Wakai","year":"1981","journal-title":"J Neurosurg"},{"key":"2021122510542204400_onco13305-bib-0017","author":"Giraldo","journal-title":"Merck Manual Professional version."},{"key":"2021122510542204400_onco13305-bib-0018","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jmoldx.2010.11.011","article-title":"Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases","volume":"13","author":"Rumilla","year":"2011","journal-title":"J Mol Diagn"},{"issue":"suppl 4","key":"2021122510542204400_onco13305-bib-0019","doi-asserted-by":"crossref","first-page":"100a","DOI":"10.1200\/JCO.2018.36.4_suppl.100","article-title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in Asian patients with pretreated recurrent or refractory gastric cancer: Preliminary results from a phase I trial","volume":"36","author":"Kang","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122510542204400_onco13305-bib-0020","article-title":"Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1","volume":"36","author":"Vugmeyster","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2020-0249","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2020-0249","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2020-0249","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/9\/e1292\/41920523\/oncolo_25_9_e1292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/9\/e1292\/41920523\/oncolo_25_9_e1292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:55:05Z","timestamp":1640429705000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/9\/e1292\/6443853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,4,23]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0249","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,1]]},"published":{"date-parts":[[2020,4,23]]}}}